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Abstract
Introduction: Non-pharmacological treatments (NPTs) have the potential to
improve meaningful outcomes for older people at risk of, or living with dementia,
but research often lacks methodological rigor and continues to produce mixed
results.
Methods: In the current position paper, experts in NPT research have specified treat-
ment targets, aims, and ingredients using an umbrella framework, the Rehabilitation
Treatment Specification System.
Results: Experts provided a snapshot and an authoritative summary of the evidence
for different NPTs based on the best synthesis efforts, identified main gaps in knowl-
edge and relevant barriers, and provided directions for future research. Experts in trial
methodology provide best practice principles and recommendations for thoseworking
in this area, underscoring the importance of prespecified protocols.
Discussion:We conclude that the evidence strongly supports various NPTs in relation
to their primary targets, and discuss opportunities and challenges associated with a
unifying theoretical framework to guide future efforts in this area.
KEYWORDS
cognitive rehabilitation, cognitive stimulation therapy, cognitive training, cognitive-behavioral
therapy for insomnia, communication treatments, framework, meditation, mild cognitive impair-
ment, multisensory treatments, music-based treatments, neuromodulation, neuropsychiatric,
non-pharmacological, nutritional interventions, occupational therapy, physical exercise training,
reminiscence therapy, subjective cognitive decline
1 INTRODUCTION
Dementia is currently one of the most pressing health-care issues,
with a worldwide rising prevalence due to the aging of the population
and the absence of a curative therapy.1,2 The estimated global total
costs of dementia were US$ 818 billion in 2015, of which the majority
was related to nursing home care and the informal care of caregivers.
Dementia also has a considerable disease impact, affecting the quality
of life of both people with dementia and their caregivers. Several dis-
eases of the brain might underlie dementia, with Alzheimer’s disease
(AD) being themost common underlying cause.
Non-pharmacological treatments (NPTs) can be effective in the
management of clinical symptoms and are likely to play an important
role in the primary and secondary prevention of dementia. Advantages
ofNPTsare that theyaregenerallywell accepted, haveminimal adverse
side effects, and can be combined with other NPTs both serially and
simultaneously, and with pharmacological treatments without major
concerns around interference. NPTs are also applicable to different
clinical stages of disease, from dementia3 tomild cognitive impairment
(MCI)4 andeven cognitively unimpaired adults at risk for dementia.5 As
such, NPTs have the potential of having a meaningful impact on cogni-
tion, well being, and quality of life throughout the course of age-related
neurodegenerative diseases.
NPTs cover a diverse and broad range of intervention categories,
including cognitive training, physical exercise, dietary treatments, art-
oriented therapy, and reminiscence therapy.6 An influential previous
meta-analysis defined NPTs as “any theoretically based, nonchemical,
focused, and replicable intervention, conducted with the patient or
the caregiver, which potentially provided some relevant benefit.”7 This
and many other systematic reviews of NPTs in aging and dementia (eg,
Bahar-Fuchs et al.8) have repeatedly pointed out the low quality of
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much of the evidence behind several NPTs. To improve the quality of
evidence for NPTs, more coherent, targeted, and well-reported trials
of higher methodological quality are needed, which will in turn lead to
firmer conclusions regarding the extent and limits of gains associated
with different types of NPT.
In 2015, the Non-Pharmacological Interventions Professional
Interest Area (NPI-PIA) group was formed as a successor to the "psy-
chosocial understanding and intervention" PIA within the Alzheimer’s
Association International Society to Advance Alzheimer’s Research
and Treatment (ISTAART). The NPI-PIA aims to address issues related
to the design, methodology, and reporting of studies of NPT in the
context of aging and dementia and to stimulate research in this area.
In 2017, at the NPI-PIA Annual Meeting at the Alzheimer’s Asso-
ciation International Conference (AAIC) in London, the Executive
Committee and members agreed that there are several issues that
affect progress in this broad field of research and deemed a position
paper necessary. The main issues discussed included the need to (1)
identify and comment on key conceptual issues and challenges in
response to rapid changes in thinking about dementia and underlying
neurodegenerative diseases and their treatment, and (2) advance
a more coherent and theoretically driven approach to the classifi-
cation and description of NPI treatments, which would lead to (3)
improved methodological and reporting standards in this area of
research.
In this paper, we offer a conceptual framework that may be useful
for organizing and classifying research in NPT. We briefly summarize
the body of work available in relation to key types of NPT in the con-
text of people with dementia or at risk of dementia due to MCI, sub-
jective cognitive decline, or biomarker profiling, and identify key chal-
lenges. Finally, we provide methodological guidelines for the design of
trials ofNPTs, and concludewith several directions for future research.
An overview of the project timeline and main milestones is shown in
Figure 1.
RESEARCH INCONTEXT
1. Systematic review: Using the Rehabilitation Treatment
Specification Framework (RTSS), the authors defined
and specified the targets and ingredients of 13 non-
pharmacological treatments (NPTs) for older people at
risk of or who live with dementia. Evidence of the effects
of these treatments was summarized based on relevant
synthesis efforts.
2. Interpretation: The targets of most NPTs are changes
in skills and habits and representations. Core/specific
ingredients and dosing parameters are sometimes diffi-
cult to prescribe, and the distinction between targets and
“downstream” aims is not always straightforward. The
overall evidence supports the efficacy of most NPTs in
relation to their primary targets.
3. Future directions: Umbrella theoretical frameworks such
as the RTSS are likely to make important contributions to
our ability to specify existing treatment, designnew treat-
ment trials, and synthesize the evidence. To improve the
quality of evidence behind NPTs, and accelerate clinical
implementation, we offer several methodological princi-
ples and guidance for those planning and designing NPT
trials.
1.1 Key conceptual issues
Herewe briefly highlight someof the conceptual issues thatwere iden-
tified when considering and choosing the appropriate treatments and
target groups for the current article.
F IGURE 1 Timeline of the Non-Pharmacological Interventions Professional Interest Area Position Paper Project
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F IGURE 2 Overview of Cochrane reviews on non-pharmacological treatments (NPTs)
1.1.1 Literature review
We performed a search of the Cochrane Database of Systematic
Reviews (September 2019), which yielded 122 systematic reviews on
a variety of NPT categories, ranging from aromatherapy to vitamin D3
supplements. The majority of NPTs focused on persons with demen-
tia. Figure 2 depicts the number of studies included in these Cochrane
studies, with most studies performed for cognitive training and Chi-
nese herbal medicine.8–10 The quality grading for the level of evidence
wasmodest at best.
1.1.2 Target populations
The current overview focuses on individuals with dementia and those
in pre-dementia at risk stages. Treatments in which the target is some-
one other than the person with or at risk of cognitive decline (eg,
family members, caregivers, general practitioners [GPs]), and treat-
ments focusing on training others (eg, caregivers) in the delivery of
a treatment are not included in the present paper. In recent years,
non-pharmacological treatment studies have broadened their focus by
targeting individuals in the pre-dementia stages, based on evidence
on dementia risk and modifiable lifestyle risk factors (eg, Livingston
et al.11), as well as an increased focus on the biological definition of
AD in pre-dementia stages.12 The pre-dementia at risk stages as dis-
cussed in the current study include those with memory complaints
and biomarker evidence for AD as well as those with MCI. Hence, the
NPTs covered in this paper can be relevant in the context of primary,
secondary, or tertiary prevention of (objective) cognitive decline and
dementia.
1.1.3 Treatments
In this paper, we use the term “treatments” or “therapy” rather than
“intervention,” in reflection of several principles: (1) While the term
“intervention” is sometimes used in the context of both the absence
and the presence of a clinical condition, treatmentmay bemore appro-
priate when a clinical condition is present. (2) The term “intervention”
is sometimes used outside of the context of health care (eg, “financial
intervention,” “educational intervention”), whereas “treatment” tends
to be used more in health-related contexts, such as the context of
the current paper. (3) The term intervention may be more appropri-
ate when a wider set of activities, including one or more treatments,
are delivered together, and in this sense could be seen as being of a
higher order. It is not uncommon to talk about an intervention that
includes treatment x or treatment y, but it is less common to talk about
a treatment that includes "interventions x or y." (4) Although "treat-
ments" are more common in the context of pharmacological interven-
tions, drugs are referred to as treatments irrespective of being a "cure."
Likewise, if the basis for this preference is that pharmacological agents
change relevant aspects of underlying pathophysiology, a similar argu-
ment can be made in relation to some non-drug treatments (eg, the
anti-inflammatory effects of exercise).
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1.1.4 Non-pharmacological
To be included in the current study, the treatment had to explicitly
target either cognitive processes or cognition in an everyday context
as a primary or secondary aim, and the link to aging needed to be clear.
Additional outcomes may or may have not been addressed as treat-
ment targets. The term "non-pharmacological" suggests that every
treatment that is not a pharmaceutical drug13 could be considered
appropriate. Importantly, the term NPT only defines what treatments
are not covered by this title and says nothing about the treatments
that are covered by this title. It does not seem to be an ideal place to
start an effort to define what it is that this paper is concerned with.
However, the main feature that could be said to be common to the
treatments covered in this paper is that they are non-drug treat-
ments. Alternative terms sometimes used, such as “psychosocial” or
“behavioral” treatments, are also unsatisfactory as several candidate
treatments that might be appropriate in this paper do not seem to be
well captured by these terms (eg, physical activity, dietary treatments,
light therapy, brain stimulation). The class of treatments that could be
considered appropriate in our context includes a very wide range of
treatments, of various degrees of specificity in terms of features or
ingredients, action mechanisms, and targets. The term NPTs/NPIs is
also broad enough to encompass treatments that are often referred to
as complementary and alternative medicines (eg, Reiki, tai chi), as well
as treatments in which the target is someone other than the person
with or at risk of cognitive decline (eg, family members, caregivers,
GPs), and treatments focusing on training others (eg, caregivers) in the
delivery of a treatment. Non-drug treatments are typically complex,
and several approaches could be used to try and meaningfully group
such treatments, including by professional discipline (eg, psychological
treatment, occupational therapy treatment), World Health Organi-
zation classification of functioning (ie, impairment, disability, classi-
fication), or by the target symptoms (eg, wandering, behavioral and
psychological symptoms in dementia [BPSD], cognitive impairment).
However, it seems impossible to propose a grouping/classification
framework for NPTs that would be entirely satisfactory or mutually
exclusive.14–17
1.2 A systematic approach to
non-pharmacological treatment specification in older
people: The Rehabilitation Treatment Specification
System (RTSS)
To address the challenges and difficulties associated with the consis-
tent labelling of NPTs, we adopted an approach that was developed
to specifying and classifying rehabilitation treatments: The Rehabil-
itation Treatment Specification System (RTSS).18 Although the RTSS
was developed within the framework of rehabilitation, we take the
view that "rehabilitation" is appropriate in the current context of treat-
ments, including preventative treatments, to support individuals in
minimizing disability and maximizing participation in meaningful life
roles. We propose that the field of NPTs in older adults could advance
F IGURE 3 The tripartite structure of treatment theory. Source:
Hart et al.18
in severalwaysbydrawingon theRTSS framework, including improving
treatment development at theprotocol stage, treatment reporting, and
replication and clinical translation, as well as by improving evidence
synthesis through identifying common ingredients and targets across
treatments.
According to the RTSS, rehabilitation treatments have a tripartite
structure (Figure 3): (1) treatment targets, defined as aspects of func-
tion the clinician is attempting to change (eg, improved semantic recall,
increased adherence to an exercise regimen); (2) ingredients, defined
as clinician actions or objects hypothesized to effect that change (eg,
instructions, modeling, coaching); and (3) mechanisms of action, the
underlying biological or psychosocial mechanisms by which change
occurs. Treatment targets are differentiated from aims, which are
aspects of change that require multiple targets (eg, improving sleep,
increasing social engagement). All targets can be classified into three
categories: Organ Functions, Skills and Habits, and Representations
(knowledge, beliefs, and attitudes). We grouped NPTs by target
category and reported ingredients and ingredient dose where that
informationwas available. Asmechanisms of action of NPTs aremostly
invisible and incompletely understood (eg, changes in some aspect
of brain function), that element of the RTSS was excluded from this
review.
2 OVERVIEW TREATMENT SPECIFICATIONS
The purpose of this paper is to advance the field of NPTs in aging and
dementia by promoting a theoretical framework that can be applied
to all NPT research. We did not intend to describe and summarize the
evidence for every type of NPT available in the context of aging. The
treatments that were included in the current paper were selected on
the basis of them being reasonably well recognized (as reflected in
the availability of at least one Cochrane Review covering that treat-
ment), and on the identification of a suitable expert contributor avail-
able to support this undertaking. In this paper, we did not include
treatments that are exclusively about environmental modification or
that primarily target care partners. These are vast areas of research
that will be covered in a separate paper. In relation to each specific
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treatment area covered in this paper, each section is organized as
follows:
1. An executive summary, containing the treatment definition, a state-
ment regarding the amount and quality of the scientific evidence
and themainmethodological challenges.
In the appendices in supporting information, the executive sum-
mary is supplemented by:
2. A treatment definition and specification using the RTSS framework
as a guide.
3. A summary statement regarding the amount and quality of the
evidence in relation to key outcomes in one or more populations
covered by the current review based on the most authoritative
source.
4. The main methodological challenges and pressing questions spe-
cific to that class of treatment.
5. A worked-out treatment specification table for that specific treat-
ment.
The treatment specification tables describe the general structure of
each treatment, as a tool for comparing typical targets and ingredients
across treatments. They are not intended to be prescriptive, as with
the exception of a fewmanualized treatments therewaswide variation
across studies in both the degree to which treatments were specified,
if at all, and implementationmethods.
An example covering all relevant components above has been
included below in relation to cognitive training. For the remainder of
the treatments covered, only the executive summaries are included in
the paper, with the complete contribution being included in the sup-
porting information Appendix.
2.1 Cognitive training
2.1.1 Executive summary
Cognitive training (CT) involves the formal training of global cognition
or specific abilities using standardized tasks.19 The assumption behind
CT is that underlying cognitive processes can be improved or main-
tained through training,8 and that training-related cognitive gains may
prevent, delay, or slow down cognitive and functional decline in older
age.20 High-quality reviews, including two systematic reviews and a
systematic overview established that CT leads to moderate improve-
ments in global cognition in people with MCI and dementia.21–24
Evidence for sustained gains, or that go beyond global cognition,
is of generally low quality due to high risk of bias in primary trials.
Improved implementation of best practice standards in CT research
in older age,25 and a better understanding of underlying mechanisms
and predictors of gain in individual recipients, are critical research
priorities.
2.1.2 Treatment specification
CT refers to the formal training of cognitive abilities and processes,
usually through repeated practice on standardized tasks designed to
reflect specific cognitive domains.8,19 Practice may focus on a single
or on multiple cognitive domains; it may include advice on the use
of, as well as practice with, internal cognitive strategies (eg, mnemon-
ics), and may be conducted individually or in small groups; and be
supervised or unsupervised. A common assumption behind CT is
that underlying cognitive processes can be improved or maintained
through training, and that training-related cognitive gainsmay be asso-
ciated with gains in day-to-day activities, or functional cognition. CT is
sometimes confused with the related but distinct approaches of gen-
eral cognitive stimulation and cognitive rehabilitation (described else-
where in this paper), and unfortunately these terms are still often
used interchangeably.23 The treatment specification is summarized in
Table 1.
Common targets and aims of CT. The primary/immediate target of
CT interventions is typically cognition, as reflected in performance on
standardized cognitive tests. Depending on the nature of the training,
the target may be a specific cognitive ability or process (eg, divided
attention), several inter-related processes, or global cognitive abil-
ity. Beyond cognitive ability, additional aims of CT treatments have
included improvement onmeasures ofmood andwell-being of the per-
son affected, subjective experience of everyday cognition, functional
independence, quality of life, and caregiver burden.
Broader contexts of CT. Process-based cognitive training has a long
history of use in clinical and healthy populations, particularly with
children and older people.26 In aging, interest in cognitive training
increased at a rapid rate since the early 1980s, with numerous stud-
ies published in cognitively healthy people, people with acquired brain
injury (eg, stroke), and peoplewith neurodegenerative diseases, partic-
ularly dementia due to AD or vascular disease.
2.1.3 Amount and quality of evidence in relation
to dementia and MCI
Numerous studies and reviews have been published on the effects
of cognitive training on cognition and other outcomes in older adults
withMCI and dementia. An influential and rigorousmeta-analysis from
2017 (Hill et al.,21 AMSTAR= 12) foundmoderate effect on global cog-
nition (k = 17, g = 0.35, 95% confidence interval [CI] = 0.20 to 0.51),
as well as small to moderate effects on several specific cognitive pro-
cesses, and on “psychosocial function.” A recently published Cochrane
Review of computerized cognitive training (CCT) in people with MCI
(Gates et al.,22 AMSTAR = 12.5) that focused on treatments lasting a
minimum of 12 weeks, and that applied stricter inclusion criteria and
risk of bias rating found, based onmeta-analysis of five trials, a moder-
ate effect of CCT on global cognition at the end of treatment relative
to active control (k= 5, g= –0.53, 95% CI= –1.06 to –0.01). Effects of
CCT were found in several specific cognitive domains as well (episodic
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TABLE 1 Specification of cognitive training against the RTSS framework
Cognitive Training. Ten-week home-basedmultidomain computer-based cognitive training for adults withmild cognitive impairment.
Target
population Target
Target Group
(Type) Ingredients Dose
Older adults
withmild
cognitive
impairment
Increased knowledge
and understanding of
age-related changes
in cognitive abilities
and links with
functional
independence
R(D) ∙ Information about age-related changes in
cognition included in Participant Information
Sheet and provided verbally by researcher
∙ Additional written information about various
cognitive abilities and their links with
everyday behaviors
∙ When first expressing interest in
the treatment study
∙ Weekly during the treatment
period
Increased capability to
use the online
training platform
S(D) ∙ Face-to-face orientation to online training
platform
∙ Demonstration of online training platform
provided by clinician/trained research staff
∙ Provision of writtenmanual describing all
necessary steps to access and complete a
training session
∙ Phone-based troubleshooting/technical
support
∙ Once in the first training session
∙ Once in the first training session
∙ Once in the first training session
∙ Once per week
Improved performance
on a composite global
measure of cognitive
function
S(D) ∙ Participant to practice on a set of 20 to 30
computerized tasks targetingmultiple
cognitive domains
∙ 30 training sessions (20minutes
each) over 10weeks
Motivation to adhere to
the treatment
R(V) ∙ Verbally delivered information about
potential short and long-term gains
associated with process training
∙ Feedback on performance delivered by the
online training platform
∙ Feedback on performance delivered over the
phone by research staff
∙ Written behavioral contract to increase
commitment to the training
∙ Barrier identificationwith problem solving
∙ Once in the first training session
∙ After each training session
∙ Once per week
∙ Once in the first training session
∙ Once in the first training session
Abbreviation: RTSS, Rehabilitation Treatment Specification System.
memory, speed of processing, working memory), but not on any non-
cognitive outcome, based on a small number of meta-analyzed trials.
Regarding people with mild to moderate dementia, a recent Cochrane
Review (Bahar-Fuchs et al.,23 AMSTAR = 14), found that relative to
active or passive control conditions, CT was associated with gains in
global cognition (k = 33, g = 0.42, 95% CI = 0.23 to 0.62), and verbal
category fluency (k = 9, g = 0.52, 95% CI = 0.23 to 0.81) at the end of
treatment, and that these gains were maintained in the medium term
(up to 12 months post-treatment). CT did not benefit non-cognitive
outcomes, and no differences were found when CT was compared to
an alternative treatment.
Evidence syntheses efforts of trials of CT in people with MCI and
dementia have consistently identifiedmethodological challenges inpri-
mary trials, which are often ranked at being at high or unclear risk of
bias in several key domains, including lack of randomization conceal-
ment, incomplete outcome data, and selective reporting. Large statis-
tical and clinical heterogeneity and imprecision of effect estimates has
led authors of recent reviews to grademost of the evidence as being of
"low" or even "very low" quality.
2.1.4 Main methodological challenges and the
most pressing questions to be addressed
Consistent implementation of best practice standards in numerous
aspects of trial planning (including registration and protocol publica-
tion), implementation (including adequate randomization, and appro-
priate control, as well as selection of outcomes andmeasures), analysis
(including dealing with missing data, protocol deviations, and multiple
comparisons), and reporting (clear, detailed, and transparent descrip-
tion of all key design features), remain significant barriers in the field of
CT.
The methodological challenges discussed above notwithstanding,
the weight of the evidence supports the view that structured process-
based cognitive training leads to at least modest improvements in
cognitive test performance in people with MCI and dementia, and
that these improvements may be maintained over a short to medium
period. What is now required is a sustained effort to improve our
understanding of how to develop more personalized CT treatments
that can be better integrated with everyday life and meaningful
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everyday activities, so that ongoing engagement is more likely and
that transfer of gains from performance on standard tests of cogni-
tion to relevant functional domains is enabled. In addition, improved
knowledge of the structural and functional effects of CT in key
brain regions and networks would help ensure that task design
and selection, as well as dosing parameters, are informed by such
changes.
3 EXECUTIVE SUMMARIES FOR REMAINING
TREATMENTS
3.1 Cognitive rehabilitation
Cognitive rehabilitation (CR) is a goal-oriented, problem-solving
behavioral therapy aimed at optimizing ability to function in everyday
life in relation to the person’s needs, wishes, and preferences.27 Robust
evidence including findings from two large trials supports the potential
of CR to improve management of functional disability.28,29 Evidence
from pilot studies30,31 and qualitative evaluations32 suggests that peo-
plewithdementia and caregivers canexperiencewider benefits such as
improved adjustment or coping, but these have not yet been captured
quantitatively in the larger trials. The typical length of follow-up in tri-
als precludes identification of long-termbenefits. Future efforts should
focus on optimizing outcomemeasurement, including longer follow-up
periods in trials, and implementing CR into health-care provision (see
Text S2 and RTSS Table S2 in supporting information).
3.2 Cognitive stimulation therapy
Cognitive stimulation therapy (CST) is a brief, manualized interven-
tion, based on the theory that appropriate and targeted mental stim-
ulation can lead to the development of new neuronal pathways. CST
aims to improve cognitive function, as well as quality of life and mood,
through themed group activities, such as discussing current affairs,
which implicitly stimulatememory, executive functioning, and language
skills. There is a large, international evidence base for group CST
demonstrating a significant beneficial effect on cognition and quality
of life in dementia.33 A Cochrane systematic review of 15 randomized
controlled trials (RCTs) found consistent benefits of CST on cognitive
function.34 A systematic review of 12 studies evaluating the UK CST
protocol found improvements in cognition, quality of life, depression,
and impact on caregivers.35 Further researcheffortsmay include inves-
tigating the relationship between adherence to outcome as well as the
effectiveness of individual CST delivered by non-family caregivers (see
Text S3 and RTSS Table S3 in supporting information).
3.3 Nutritional treatments
Nutritional treatments aim to modify dietary intake of micronutri-
ents (vitamins andminerals) and/ormacronutrients (proteins, fats, car-
bohydrates) through specific supplements or in combination through
diet.36,37 Adequate nutrition is essential for brain health because of
its involvement in biological pathways that reduce oxidative stress and
inflammation, promotevascular health, aswell as improveneuronal cell
signaling and function of neuronal cells.38–40 Despite limited evidence
on the effect of nutritional treatments on cognitive outcomes, and
significant methodological challenges, data are promising.41–47 Single
trials have shown a beneficial effect of B vitamin supplementation
on memory performance in MCI patients with high homocysteine,41
as well as improvements in cognitive performance by supplementa-
tion of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA),
and flavonols.42–45 Large trials on vitamin E supplementation demon-
strated delayed progression in functional decline and AD.46,47 Future
research should replicate these findings by focusing on conducting clin-
ical trials in sufficient size and duration, as well as rigorous procedures
for randomization and blinded testing (see Text S4 in supporting infor-
mation).
3.4 Physical exercise training
Physical exercise training is based on planned and/or structured activ-
ity which may be aerobic exercise, resistance training,48 or a combi-
nation (multimodal) or mind-body exercise (eg, tai chi). The evidence
for a positive effect of aerobic training on global cognition is growing
with consistent medium effect sizes reported from systematic reviews
and meta-analyses.49–51 Resistance training usually requires supervi-
sion and thereforemore resources and intensive treatments to achieve
effective adherence.While promising, evidence on this type of training
has yet to reach the same consistency, quality, and volume as that of
aerobic training. Future research should investigate whether exercise
modes are domain-specific and identification of strategies to enhance
adherence to exercise training iswarranted (seeText S5 andRTSSTable
S4 in supporting information).
3.5 Sleep treatments
Insomnia is defined as problems with sleep quality or quantity,
including difficulty initiating sleep, repeated prolonged awakenings,
and/or nonrestorative sleep.52,53 Several meta-analyses of cognitive-
behavioral therapy for insomnia (CBT-I) support the finding that sleep
disturbance is very amenable to change in both young and older adults,
with treatment resulting in robust improvements in sleep quantity
and quality.54–56 Future efforts should study the neuronal overlap and
causal mechanisms between sleep disturbance and cognitive decline
in individuals ranging from cognitively normal to impaired, to decide
which approaches should be used for which populations and at which
point in time.
In addition to insomnia, sleep disturbances in persons with demen-
tia (PWD) also include hypersomnia, excessive motor activity at night,
and hallucinations or other behavioral problems. Sleep specialists
aim to target nocturnal neurocognitive symptoms in PWD through
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implementation of sleep promotion strategies (eg, bright light, regula-
tion of sleep-wake schedules, decreasing arousal, increasing daytime
activity) based upon CBT of sleep. While studies have established
the effectiveness of various environmental and multi-component
treatments to improve sleep in PWD,57–62 there are currently no
meta-analyses or systematic reviews of CBT-I in those with MCI or
dementia. Specific CBT-related methodological challenges included
lack of standard treatment components and measurements and need
for caregivers who can oversee treatment recommendations and sleep
assessments. Future research should focus on the understanding the
role of sleep disturbances in the pathogenesis of dementia and the
underlying mechanisms of sleep and cognitive decline, as well as how
dementia diagnostic subtypes and age of onset may impact treat-
ment response (see Text S6 and S7, and RTSS Table S5 in supporting
information).
3.6 Meditation
Meditation refers to a family of emotional and attentional regulatory
training exercises.63,64 Meditation training programs, usually includ-
ing sessions with an instructor as well as daily home practice, have
been shown to improve cognition, well-being, and health in older age
and may contribute to delaying the onset of dementia.65–67 Poten-
tial mechanisms underlying the effect of meditation include effects
on inflammation, stress and emotion regulation, brain microstruc-
ture and/or macroscopic brain structure, brain glucose metabolism
and brain connectivity, and effects on telomere length and telom-
erase activity.67–70 There are currently no meta-analyses or system-
atic reviews specifically focused on meditation as a single domain
treatment for MCI and dementia. Though there is limited formal
evidence, pilot RCTs and cross-sectional studies showed effects on
cognition,71,72 psycho-affective factors,71,73 sleep quality,73 and qual-
ity of life.73,74 Future research should include longitudinal studies and
RCTs, with large samples and using clinically meaningful biological and
neuroimaging biomarkers (see Text S8 and RTSS Table S6 in supporting
information).
3.7 Reminiscence therapy
Reminiscence therapy is the recollection and sharing of personal
memories and experiences. It aims to promote cognition, commu-
nication, identity, mood, social connectedness, mental health, well-
being, and quality of relationships.75,76 It can be offered individually
or in groups. Recently, systematic reviews andmeta-analyses,77–80 and
(an abridged) Cochrane review were published.76,81 Evidence showed
small significant positive effects on quality of life, mood, BPSD, cog-
nition, and communication in people with mainly mild to moderately
severe dementia. Effects differed depending on treatment modality
and setting. Future efforts should include large RCTs with detailed
descriptions of the treatment protocols, targets, aims, and target
groups (see Text S9 and RTSS Table S7 in supporting information).
3.8 Music-based treatments
Music-based treatments are classified as active or receptive musical
activities that aim to address multiple non-musical outcomes (eg,
cognitive, psychosocial, communication, and physical goals), often
simultaneously. Active treatments include instrument playing, singing,
songwriting, and moving to music. Receptive treatments involve
listening to recorded or live music. Music therapy treatments (goal-
based therapeutic musical interaction with a trained therapist), are
distinguished from music activities that can be implemented by other
clinicians, caregivers, or self-administered. A recent Cochrane review
summarized the effect of multiple RCTs examining both active and
receptive music treatments and reported evidence for reductions in
depression and overall behavioral problems, but no effect on agitation,
and low-quality evidence for reductions in anxiety and quality of life
and little to no effect on cognition.82 For other areas, such as anxiety
and social behavior, the Cochrane review found not enough evidence
to determine effects. Other recent reviews have found evidence that
music therapy is effective in reducing agitation, anxiety, depression,
and other neuropsychiatric symptoms.83–85 There is disagreement
between somepublishedmeta-analyses onwhether activeor receptive
treatments are more effective for specific outcomes. The low quality
of the current evidence highlights that improvements for future
research are necessary, most specifically improving design quality and
comparing different music-based treatments (receptive versus active)
and dosage (see Text S10 andRTSS Table S8 in supporting information).
3.9 Communication treatments
Communication interventions target a construct referred to as “quality
of communication life,” defined as the extent to which a person’s com-
munication acts allow a meaningful participation in life situations.86
Communication treatments aim to maintain or improve quality and
quantity of meaningful communication interactions. These treatments
can be divided into direct and indirect treatments. Direct treatments
are primarily language stimulation tasks and activities, delivered indi-
vidually or in groups. Indirect treatments include training family and
professional carers in strategies for effective communication, modify-
ing environments to facilitate communication, and developing thera-
peutic routines and activities that promote communication. A current
challenge is the tendency for late (or no) recognition of communication
problems in MCI and dementia. The level of evidence is currently lim-
ited due to a lack of controlled studies, and future efforts should focus
on this (see Text S11 and RTSS Table S9 in supporting information).
3.10 Multisensory treatments
Multisensory treatments stimulate the senses (sight, hearing, taste,
touch, smell) to compensate for sensory deprivation or to restore an
imbalance such as suboptimal pacing of stimulating and calming sen-
sory input.87,88 These treatments mostly aim to improve behavior,
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quality of life, well-being, or functioning and are often suitable formod-
erate dementia. Snoezelen and sensory gardens involve supervised
presence in environments equipped with tools to stimulate senses,
and Sonas is a structured group program to stimulate all senses.
Although all of these treatments have been studied in some RCTs, the
treatments were heterogeneous and study samples small.89–94 Taken
together, the evidence base for effects is still modest. At this point,
well-designedRCTs that allow studying subgroup effects are necessary
to advance the field (see Text S12 and RTSS Table S10 in supporting
information).
3.11 Occupational therapy
The primary aim of occupational therapy is to optimize occupational
performance by enabling people to participate in the activities that
they want, need, or are expected to do.95 One of the theoretical mod-
els is the person-environment-occupation model,96 which portrays
the relationship between the capabilities and characteristics of the
person—the physical, social, and cultural environment—and the tar-
get occupation. The level of evidence for some outcomes is considered
"moderate", with a number of high quality RCTs supportive of improve-
ments in activities of daily living (ADL), quality of life and reductions in
problem behavior.97 Key challenges for the field of occupational ther-
apy include determining the optimal characteristics of the treatment,
dose, methods of service delivery, and subgroupsmost likely to benefit
from treatment (see Text S13 and RTSS Table S11 in supporting infor-
mation).
3.12 Neuromodulation
Neuromodulation involves the introduction of energy (eg, electrical,
magnetic) into the brain with the goal of altering neurophysiology.
Treatments include transcranial magnetic stimulation (TMS) and tran-
scranial direct current stimulation (tDCS). This treatment is currently
not yet clinically approved for the use in cognitive deficits. Exist-
ing meta-analyses and reviews provide conflicting evidence for the
effects of neuromodulation in those across the dementia spectrum
but are limited by a small number of primary research studies with
small sample sizes.98,99 Research into neuromodulation needs focus
on dosing parameters, including dose-response relationships, and the
combination with and timing of other (non)pharmacological agents.
This will likely reduce heterogeneity in response and facilitate clini-
cal translation efforts (see Text S14 and RTSS Table S12 in supporting
information).
4 GENERAL METHODOLOGICAL
CONSIDERATIONS
Several NPTs show a clear therapeutic potential, but the depth and
breadth of the evidence base so far varies across the different treat-
ments. The body of evidence concerning cognitive training21 and
physical exercise10 appears to be more advanced relative to other
treatments covered. A common thread through most of the primary
research and associated systematic reviews is the need to improve
the quality, transparency, and clinical relevance of NPT trials in aging
and dementia. Realizing the potential of NPTs will strongly depend
on future trials being developed against a well-articulated rationale,
a stronger focus on hypothesis testing, and trials being more rigor-
ously designed. Critical elements including treatment development,
trial design, and outcomemeasurement should be carefully considered
early in the planning phase to minimize risk of bias and to maximize
generalizability of findings. Below, we provide recommendations con-
cerning someof the key design questions that need to be considered by
those designing such trials (for an overview, see Figure 4 andTable 2).
Existing evidence and pilot work should inform key factors such as
treatment content and dose, ideally based on systematic reviews that
investigate the moderating effects of design factors. The dose (inten-
sity, frequency, and length) should consider not only possible dose
responsiveness, but also matters of compliance and adherence (in par-
ticular for self-administered and unsupervised treatments) that should
be measured using reliable methods.100,101 Ideally, a small-scale pilot
study should be conducted to obtain the information before a "Phase I
study" is carried out. A key issue of increasing importance in treatment
development is creating opportunities for key stakeholders (patients,
care partners, and clinicians) to be involved and provide input as appro-
priate into the development of the treatment protocol, and through the
course of its evaluation.
Treatment targets (eg, cognition, behavior, or risk factor) and their
operationalization should occur at the start of the planning pro-
cess. Key questions to ask are whether the treatment is expected to
affect proposed biological, clinical, or functional target(s) and aims,
and the RTSS framework can be useful in thinking through these
issues. Whether existing, validated measures of the proposed targets
are available and can be used, and how frequently outcomes will be
assessed, are questions of paramount importance. Where possible,
selection of outcome measures should be based on standard diagnos-
tic techniques andensuremeasureshaveevidenceof adequatepsycho-
metric properties, including test-retest reliability, validity, and sensitiv-
ity to detect change.
Researchers should ensure they carefully consider the research
question(s) they would like the trial to address, and whether these
imply trials that emphasize feasibility/acceptability of a treatment,
dose-response issues, superiority or non-inferiority in relation to
another treatment, an active control condition, or treatment as usual.
These research questions are of great importance and should directly
impact decisions regarding the most appropriate trial design. In
addition to determining whether a randomized controlled design is
feasible and appropriate, consideration should be given to whether
assignment to treatment conditions, and outcome evaluations can be
blinded. Moreover, considerations should include whether experimen-
tal and comparison conditions should take the form of parallel arms,
cross-over or delayed start to one arm, or a factorial randomization to
examinemore than one treatment.
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F IGURE 4 Overview of methodological considerations in the design of non-pharmacological treatments
TABLE 2 Checklist for the design of a non-pharmacological treatment trial
Stage Checklist items Considerations
(A) 1. Duration of trial
follow-up
2. Population selection
Duration of follow-up should be reasonable in view of past studies and evidence. For the population
selection, consider whether targeted sample characteristics are justifiable, in terms of age range, sex,
genetics, and other characteristics.
(B) 1. Conceptualization of
mechanisms
Consider the alignment between treatment target and outcomes
(C) (D) 1. Operationalize
treatment targets
2. Dose considerations
For specifying treatment targets, consider the use of the RTSS framework. For dose considerations,
adequate dosing should be carefully considered, or multiple armswith different dosingmight be part of
the study design.
(E) (F) 1. Operationalize
outcomes
2. Trial intervals and
duration of follow-up
Adequately selected and operationalized outcomes are key to a treatment trial. Primary outcomes,
co-primary outcomes, dual primary outcomes, exploratory outcomes, secondary outcomes should be
carefully considered. For the operationalization of the outcomes it is recommended to use already
validatedmeasures, taking into account whether the scale is validated in the population of interest, as
well as evidence for the sensitivity to capture changes over time (longitudinal validation) in relationship
to the proposed assessment time period.When creating new outcomemeasures, consider an
independent validation pilot study when planning your study.
When planning trial intervals, consider how often the outcomes should bemeasured, based on past
evidence. Clearly monitor and define adherence (eg, days completed?, % of duration completed?).
(G) 1. Statistical analyses Carefully consider what analytical models are best suited for establishing the hypothesizedmechanisms, as
well as the approach tominimize the required sample size. Consider whether changes are expected in a
linear or non-linear fashion.
Define threshold of statistical significance (consider multiple comparison adjustment) and defineminimum
effect size upfront. Consider potential drop-out mechanisms, andwhat kinds of sensitivity analyses need
to be proposed.
Intention to treat (ITT) analyses vs modified ITT analyses (eg, include those with at least one follow-up) vs
per protocol analyses (PP). Both analyses are recommendedwith ITT analyses being the gold standard.
Clearly propose up front what type of analyses will be conducted.
Include sample size estimates and simulations. Is the sample size proposed adequate and feasible, provide
evidence and justifications.
(H) 1. IRB approval
2. Clinicaltrials.gov
registration
Consider how longwill it take to receive ethical approval, whether you need site-specific approvals
(multicenter studies), and other issues such as sponsor approval, confirmation of insurance, approval
from health-care providers or regulatory bodies for allied health-care professionals, approvals from
consumer groups, inclusion of people with lived experience on research committees, national or
international approval or validation for device trials, secure data collection and datamanagement plans.
If hypotheses are made regarding more than one main outcome, it
is important to determine whether the outcomes should be treated as
co-primary, orwhether oneoutcome should be consideredprimary and
another secondary. These distinctions between primary and secondary
outcomes are important for a range of reasons, including for establish-
ing issues related to statistical power and interpreting the clinical rele-
vance of the finding. Putative effect moderators need to be carefully
considered to maximize the generalizability and clinical relevance of
the findings (positive or negative).
4.1 Essential ingredients for the next generation
of robust non-pharmacological trials
A power calculation should be conducted to inform recruitment and
this should be based on the expected level of change in the primary
outcome(s) based on pilot studies and/or past literature. The sources
used to estimate the expected treatment effect for power calculations
(eg, studies which provided the information on expected changes and
its standard deviation or coefficient and its standard error) need to be
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clearly stated. In recent years, a growing number of trials include mea-
surements of digital biomarkers (eg, motion sensors). Issues related to
the frequency of such measurements (eg, continuously, daily, monthly)
and processing of the data could have critical implications for power
estimates102 and this needs to be carefully considered, especially if
such markers are used as trial outcomes. Power and sample-size tar-
gets should also take into account expected rates of attrition, death,
or discontinuation. If attrition is likely to be greater in one of the trial
arms than other arms, this needs to be taken into account, and simi-
larly if recruitment to one of the trial arms is expected to bemore chal-
lenging, this too should be taken into account at the protocol stage. The
Consolidated Standards of Reporting Trials Statement (CONSORT103),
initially developed in the context of biomedical trials, was recently
extended to accommodate the trials in behavioral and social sci-
ences (CONSORT-SPI104). Researchers are encouraged to consider
the items in the CONSORT-SPI statement at the protocol planning
phase to make sure that all the basic requirements in RCTs are cov-
ered. Intention-to-treat (ITT) analyses are the gold standard because
they eliminate potential selection bias associated with only analyz-
ing data from participants who adhered to their assigned treatment
arm.However, CONSORTguidelines recommend that both ITT andper
protocol (PP) analyses be reported for all outcomes so that readers
can interpret the effect of a treatment in a more informed manner.105
This practice is particularly relevant in NPT trials as personal pref-
erences and individual differences often affect adherence levels and
this has implications to whether a treatment can be sustained in a
longer term. Understanding factors associated with treatment adher-
ence is critical in considering the real-world application of a treatment
and “dose-response” effects. The selection process from the ITT sam-
ple to the PP sample and the difference in effect sizes between the
two analyses could provide key information in estimating translational
effects or sustainability of a treatment in the real world. Planned sub-
group and adjusted analyses should be clearly outlined at the protocol
stage.
Finally, the planned trial should be considered pragmatically in a
real-world context, in particular with regard to the (recruitment of) the
target population. Regulatory aspects need to be taken into consider-
ation, with the local regulatory agency for drug and device trials, the
university, or sponsor’s research governance offices as good starting
points for this information.
5 CONCLUDING REMARKS
The aim of this paper was to summarize the body of work available in
relation to key types of NPT in the context of aging and dementia stud-
ies, identify key challenges for different NPTs, and provide method-
ological guidelines for the design of future trials of NPTs. Our work
thereby represents an important step in the process of advancing the
theoretical andmethodological rigor of research into NPTs.
Numerous treatment approaches fall under the umbrella term
"NPT." The current paper focused on a sample of these approaches
for which there is a relatively robust body of evidence, and applied
the RTSS framework to identify targets, ingredients, and dosing
parameters for these treatments. The importance of developing prac-
tices that promote the replicability of treatment studies cannot be
overstated,106 and to do that we need systematic descriptions of those
practices.18 The work in the present paper underscores some of the
challenges and opportunities associated with using a single theoreti-
cal framework to describe, specify, and prescribe very diverse treat-
ments. When examined using the RTSS framework, it can be clearly
seen that many or most treatments involve targets that fall primarily
into the skills and the representations target groups. This is not surpris-
ing given that NPTs typically (with some exceptions) do not have organ
functions as their direct targets. The RTSS framework also revealed
themes across treatments that go by different names and are offered
by different health-care providers, including themes in targets (eg,
improving memory), and ingredients (eg, physical and mental exercise
inMCI, environmental modification in dementia). Articulating core tar-
gets, ingredients, and dosing parameters of given treatmentswas often
challenging. Ingredients and dosing parameters were often omitted
from treatments described in the literature, or described only in gen-
eral terms (eg, “enabling ingredients,” weeks of treatment). Likewise,
targets of a treatment were not always stated in published reports.
Even for the expert contributors, distinguishing between treatment
targets and downstream aims required some effort. A benefit of using
the RTSS in this project was that it prompted critical thinking and dis-
cussion about what treatments were actually intended to achieve, and
researchers’ theories about what aspects of treatment would effect
that change.
Review of the evidence in relation to the different NPTs shows that
while treatments may be effective in bringing about change in their
immediate targets, effectiveness for changing downstream aims is less
conclusive. TheRTSSwas helpful here aswell, as it revealed treatments
inwhich theprimary outcomewas actually an aim rather than the target
of the treatment. A commonexamplewas cognitive training-type treat-
ments that were hypothesized to improve everyday cognitive function,
but had actual treatment targets like “improved accuracy of recall” on
memory tasks, used ingredients designed to improve recall on those
tasks, and measured outcomes via scores on memory tests and sub-
jective everyday memory measures. Results of many studies showed
improvements on tests but not in everyday life. Those results are not
surprising because change in everyday life requires different ingredi-
ents, including ingredients and targets related to factors like family
education and participant awareness. A treatment can therefore be
dismissed as ineffective when the problem is a mismatch among ingre-
dients, targets, and outcome measures. Using the RTSS can promote a
better match across these variables and clearer specification of what
the treatment is intended to achieve, and thus help reveal treatment
effects. A further point that is also evident is that research to date has
focused predominantly on the well-established clinical stages of MCI
and dementia, with a very limited literature evaluating the benefits
fromNPTs on people with subjective cognitive decline.
Given accumulated supportive evidence in relation to some
treatments (eg, cognitive training, music therapy), it is important
that researchers collaborate effectively with industry partners,
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government, and non-government health-care organizations to design
and carry out rigorous yet pragmatic implementation studies embed-
ded within existing service frameworks. Such research should also
aim to understand effective methods to shift attitudes of prescribing
clinicians, so that appropriate NPTs be offered to individuals along
the cognitive aging continuum. These studies are also important to
further our understanding of the efficacy of different NPTs in the
context of the etiological heterogeneity of dementia and MCI syn-
dromes. Even in areas where the research is not mature enough to
move to implementation studies (eg, mindfulness), increasing efforts
should be now directed toward a better understanding of person-
and treatment-related factors that moderate treatment efficacy and
predict treatment response at the level of the individual patient.
Common barriers that were reported included the inadequacy of
reporting of relevant data regarding treatment adherence, motivation,
and various personal characteristics that are likely to play a role in
treatment adherence, persistence, and response. Along with improved
specification of treatments, the field of NPTs will require continu-
ously improving reporting standards, to make sure that evidence
can be adequately synthesized and that replication efforts are not
wasted.
The current study has several limitations. First, although we
intended to provide a comprehensive overview of NPTs in aging and
dementia, we acknowledge that several treatment areas were not
covered. This was based on our decision to only include treatments
for which substantial research evidence was available, as reflected
primarily by the availability of at least one Cochrane review. Emerging
treatment approaches for which there is growing interest, such as
multidomain lifestyle interventions like the FINGER trial,107 and
specific diets such as the Mediterranean and MIND diet108 were
therefore not included. Regarding mindfulness, we are of the opinion
that the current work can aid in an improved understanding of person
and treatment related factors. A second limitation concerns the RTSS
framework terminology used in the current paper, which in some cases
might differ from conventions in this research field (eg, "target" instead
of "outcome"). In our view, adopting an existing and well-established
framework outweighed those limitations.
The many advantages of NPTs are well recognized. We hope that
the theoretical framework proposed and the methodological guide-
lines offered in the current study would help researchers designing
the next generation of NPT studies in such a way that more reliable
evidence and evidence synthesis efforts are produced, and that the
optimal approaches to NPTs, tailored to the specific characteristics of
individuals, will be developed and lead to meaningful outcomes in the
lives of people with dementia, or at risk of dementia.
ACKNOWLEDGMENTS
The NPI-PIA executive committee is grateful to the many contribu-
tors who have worked closely with us on this project. We would like
to acknowledge in particular the guidance and vision of Prof Linda
Clare and Henry Brodaty. We are very grateful to Prof Lyn Turkstra
for generously giving much of her time to help the section contribu-
tors develop their work against the RTSS framework and for providing
numerous insights and comments on the paper. We are grateful to the
wider NPI-PIA membership and ISTAART for supporting and encour-
aging this effort.
This work is dedicated to the memory of Dr. Martha Clare Mor-
ris, a visionary researcher who shaped much of the work on the links
between nutrition and dementia and who led the nutrition section of
this paper.Weare confident that shewouldhavebeenproudof theout-
come.
This manuscript was facilitated by the Alzheimer’s Association
International Society to Advance Alzheimer’s Research and Treatment
(ISTAART), through the Non-Pharmacological Interventions, Clini-
cal Trial Advancement and Methods, and Nutrition, Metabolism and
Dementia professional interest areas (PIAs). The views and opinions
expressed by authors in this publication represent those of the authors
and do not necessarily reflect those of the PIA membership, ISTAART
or the Alzheimer’s Association.
CONFLICTS OF INTEREST
GC reports coordination of a European Union Horizon 2020 program
(Silver-Sante Study-Medit-Ageing), with no stock options, patent or
royalties. AL reports being co-investigator in clinical trials of comput-
erized cognitive training using programs provided free-of-charge by
HAPPYneuron Inc. and Synaptikon GmbH. GR and AS report offer-
ing training courses in CST and receiving occasional private income
for training courses for dementia outside usual work. The remaining
authors report no relevant conflict of interest.
REFERENCES
1. Alzheimer’s Association, Alzheimer’s disease facts and figures.
Alzheimer’s Dement. 2015;11(3):332-384.
2. Prince M, Herrera C, Knapp M, et al., World Alzheimer report 2016:
improvinghealthcare for people livingwith dementia: coverage, qual-
ity and costs now and in the future. London, UK: Alzheimer’s Disease
International (ADI). 2016:131.
3. American Psychiatric Association. (2013). Diagnostic and Statistical
Manual of Mental Disorders (5th ed.).Washington, DC: Author.
4. PetersenRC.Mild cognitive impairment.CONTINUUM: Lifelong Learn-
ing Neurol. 2016;22(2 Dementia):404.
5. Jessen F, Amariglio RE, Boxtel MV, et al. A conceptual framework
for research on subjective cognitive decline in preclinical Alzheimer’s
disease. Alzheimer’s Dement. 2014;10(6):844-852.
6. Scales K, Zimmerman S, Miller SJ. Evidence-Based nonpharmacolog-
ical practices to address behavioral and psychological symptoms of
dementia.Gerontologist. 2018;58(suppl_1):S88-S102.
7. Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies
inAlzheimer’s disease: a systematic reviewof efficacy.DementGeriatr
Cogn Disord. 2010;30(2):161-178.
8. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive
rehabilitation for mild to moderate Alzheimer’s disease and vascular
dementia. Cochrane Database Syst Rev. 2013(6):CD003260.
9. van der Steen JT, van Soest-Poortvliet MC, van der Wouden JC,
et al. Music-based therapeutic interventions for people with demen-
tia (Review). Cochrane Database Syst Rev. 2017(5):CD003477.
10. Young J, Angevaren M, Rusted J, et al. Aerobic exercise to improve
cognitive function in older people without known cognitive impair-
ment. Cochrane Database Syst Rev. 2015(4).
11. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention,
intervention, and care. Lancet. 2017;390(10113):2673-2734.
14 SIKKES ET AL.
12. Jack CR Jr, Albert MS, Knopman DS, et al. NIA-AA Research
Framework: toward a biological definition of Alzheimer’s disease.
Alzheimer’s Dement. 2018;14(4):535-562.
13. Pharmacists Pharma Journal. http://www.pharmacistspharma
journal.org/. 2010 [cited May 14, 2019]. http://www.pharmacists
pharmajournal.org/2010/11/definitions-of-drug-radioactive-drug_
11.html#.XNoXoFszaUk.
14. Michie S, Abraham C. Advancing the science of behaviour change: a
plea for scientific reporting. Addiction. 2008;103(9):1409-1410.
15. Michie S, Prestwich A. Are interventions theory-based? Devel-
opment of a theory coding scheme. Health Psychol. 2010;29(1):
1-8.
16. Michie S, van Stralen MM, West R. The behaviour change wheel:
a new method for characterising and designing behaviour change
interventions. Implement Sci. 2011;6:42.
17. Hart T, Dijkers MP, Whyte J, et al. Toward a theory-driven clas-
sification of rehabilitation treatments. Arch Physical Med Rehabil.
2014;95(1):S33-S44. e2.
18. Hart T, Dijkers MP, Whyte J, et al. A theory-driven system for the
specification of rehabilitation treatments. Arch Physical Med Rehabil.
2019;100(1):172-180.
19. Clare L, Woods RT, Moniz Cook ED, et al. Cognitive rehabilitation
and cognitive training for early-stage Alzheimer’s disease and vascu-
lar dementia. Cochrane Database Syst Rev. 2003(4):CD003260.
20. Gates NJ, Sachdev P. Is cognitive training an effective treatment
for preclinical and early Alzheimer’s disease? J Alzheimer’s Dis.
2014.
21. Hill NT, Mowszowski L, Psych D, et al. Computerized cognitive train-
ing in older adults withmild cognitive impairment or dementia: a sys-
tematic review andmeta-analysis. Am J Psychiatry. 2017;174(4):329-
340.
22. Gates NJ, Vernooij RWM, Di Nisio M, et al. Computerised cognitive
training for preventingdementia inpeoplewithmild cognitive impair-
ment. Cochrane Database Syst Rev. 2019;3:Cd012279.
23. Bahar-Fuchs A, Barendse MEA, Bloom R, et al. Cognitive training for
people with mild to moderate dementia. Cochrane Database Syst Rev.
2019;3:Cd013069.
24. Gavelin HM, Lampit A, Hallock H, et al. Cognition-oriented treat-
ments for older adults: a systematic overview of systematic reviews.
Neuropsychol Rev. 2020;10.
25. Simons DJ, Berger JO, Sellke TM, et al. Do "brain-training" programs
work. Psychol Sci Public Interest. 2016;17(3):103-186.
26. Katz B, Shah P, Meyer DE. How to play 20 questions with nature and
lose: reflections on 100 years of brain-training research. Proc Natl
Acad Sci. 2018;115(40):9897-9904.
27. Clare L, Teale JC, Toms G, et al. Cognitive rehabilitation, self-
management, psychotherapeutic and caregiver support interven-
tions in progressive neurodegenerative conditions: a scoping review.
NeuroRehabilitation. 2018;43(4):443-471.
28. Amieva H, Robert PH, Grandoulier AS, et al. Group and individual
cognitive therapies in Alzheimer’s disease: the ETNA3 randomized
trial. Int Psychogeriatr. 2016;28(5):707-717.
29. Clare L, Aleksandra K, Oyebode JR, et al. Individual goal-oriented
cognitive rehabilitation to improve everyday functioning for peo-
ple with early-stage dementia: a multicentre randomised con-
trolled trial (the GREAT trial). Int J Geriatr Psychiatry. 2019;34(5):
709-721.
30. Clare L, LindenDEJ,WoodsRT, et al. Goal-oriented cognitive rehabil-
itation for people with early-stage Alzheimer disease: a single-blind
randomized controlled trial of clinical efficacy. Am J Geriatr Psychia-
try. 2010;18(10):928-939.
31. Hindle JV, Watermeyer TJ, Roberts J, et al. Goal-orientated cog-
nitive rehabilitation for dementias associated with Parkinson’s
disease-A pilot randomised controlled trial. Int J Geriatr Psychiatry.
2018;33(5):718-728.
32. Clare L, Kudlicka A, Oyebode JR, et al. Goal-oriented cognitive reha-
bilitation for early-stage Alzheimer’s and related dementias: the
GREAT RCT.Health Technol Assess. 2019;23(10):1-242.
33. Orrell M, Aguirre E, Spector A, et al. Maintenance cognitive
stimulation therapy for dementia: single-blind, multicentre, prag-
matic randomised controlled trial. Br J Psychiatry. 2014;204(6):
454-461.
34. Woods B, Spector A, Orrell M, et al. Cognitive stimulation to improve
cognitive functioning in people with dementia. Cochrane Database
Syst Rev. 2012(2):Cd005562.
35. Lobbia A, Carbone E, Faggia S, et al. The efficacy of cognitive stim-
ulation therapy (CST) for people with mild-to-moderate dementia: a
review. Eur Psychol. 2019;24(3):257-277.
36. Papanikolaou Y, Jones JM, Fulgoni VL. Several grain dietary patterns
are associated with better diet quality and improved shortfall nutri-
ent intakes in US children and adolescents: a study focusing on the
2015-2020 Dietary Guidelines for Americans. Nutr J. 2017;16(1):
13.
37. U.S. Department of Agriculture and U.S. Department of Health and
Human Services. Dietary guidelines for Americans, 2010. 7th Edition,
Washington, DC: U.S. Government PrintingOffice. 2010.
38. Miller ER, 3rd, Erlinge TP, Sacks FM, et al, A dietary pattern
that lowers oxidative stress increases antibodies to oxidized LDL:
results from a randomized controlled feeding study. Atherosclerosis.
2005;183(1):175-182.
39. Gadgil MD, Appel LJ, Yeung E, et al. The effects of carbohydrate,
unsaturated fat, and protein intake onmeasures of insulin sensitivity:
results from the OmniHeart trial. Diabetes Care. 2013;36(5):1132-
1137.
40. Azadbakht L, Surkan PJ, Esmaillzade A, et al. The dietary approaches
to stop hypertension eating plan affects c-reactive protein, coagula-
tion abnormalities, and hepatic function tests among type 2 diabetic
patients. J Nutr. 2011;141(6):1083-1088.
41. de Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical out-
comes of homocysteine-lowering B-vitamin treatment in mild cogni-
tive impairment: a randomized controlled trial. Int J Geriatr Psychiatry.
2012;27(6):592-600.
42. Lee LK, Shahar S, Chin AV, ,et al. Docosahexaenoic acid-concentrated
fish oil supplementation in subjects with mild cognitive impairment
(MCI): a 12-month randomised, double-blind, placebo-controlled
trial. Psychopharmacology. 2013;225(3):605-612.
43. Bo Y, Zhang X, Wang Y, et al. The n-3 polyunsaturated fatty acids
supplementation improved the cognitive function in the Chinese
elderly with mild cognitive impairment: a double-blind randomized
controlled trial.Nutrients. 2017;9(1):54.
44. Zhang YP, Miao R, Li Q, et al. Effects of DHA supplemen-
tation on hippocampal volume and cognitive function in older
adults with mild cognitive impairment: a 12-month randomized,
double-blind, placebo-controlled trial. J Alzheimers Dis. 2017;55(2):
497-507.
45. Desideri G, Kwik-Uribe C, Grassi D, et al. Benefits in cognitive
function, blood pressure, and insulin resistance through cocoa fla-
vanol consumption in elderly subjects with mild cognitive impair-
ment: the cocoa, cognition, and aging (CoCoA) study. Hypertension.
2012;60(3):794-801.
46. DyskenMW, SanoM,Asthana S, et al. Effect of vitamin E andmeman-
tine on functional decline in Alzheimer disease: the TEAM-AD VA
cooperative randomized trial. Jama. 2014;311(1):33-44.
47. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegi-
line, alpha-tocopherol, or both as treatment for Alzheimer’s
disease. Alzheimer’s Dis Cooperative Study. N Engl J Med.
1997;336(17):1216-1222.
48. Garber CE, Blissmer B, Deschenes MR, et al. Quantity and qual-
ity of exercise for developing and maintaining cardiorespiratory,
musculoskeletal, and neuromotor fitness in apparently healthy
SIKKES ET AL. 15
adults: guidance for prescribing exercise. Medi Sci Sports Exercise.
2011;43(7):1334-1359.
49. Zheng G, Xia R, ZhouW, et al. Aerobic exercise ameliorates cognitive
function in older adults with mild cognitive impairment: a systematic
review and meta-analysis of randomised controlled trials. Br J Sports
Med. 2016;50(23):1443-1450.
50. Song D, Yu DSF, Polly WCL, et al. The effectiveness of physical exer-
cise on cognitive and psychological outcomes in individuals withmild
cognitive impairment: a systematic review and meta-analysis. Int J
Nursing Studies. 2018;79:155-164.
51. Ströhle A, Schmidt DK, Schult F, et al. Drug and exercise treat-
ment of Alzheimer disease and mild cognitive impairment: a sys-
tematic review and meta-analysis of effects on cognition in ran-
domized controlled trials. Am J Geriatr Psychiatry. 2015;23(12):1234-
1249.
52. AssociationAP.Diagnostic and statisticalmanual ofmental disorders
(DSM-5®). 2013. Am Psychiatric Pub. 2013.
53. American Academy of Sleep Medicine. International Classification
of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep
Medicine. 2014.
54. Geiger-Brown JM, Rogers VE, LiuW, et al. Cognitive behavioral ther-
apy in persons with comorbid insomnia: a meta-analysis. Sleep Med
Rev. 2015;23:54-67.
55. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of
behavioral interventions for insomnia and their efficacy in middle-
aged adults and in older adults 55+ years of age. Health Psychol.
2006;25(1):3-14.
56. Trauer JM, QianMY, Doyle JS, et al. Cognitive behavioral therapy for
chronic insomnia: a systematic review and meta-analysis. Ann Intern
Med. 2015;163(3):191-204.
57. Cassidy-EagleE, SiebernA,Unti L, et al.Neuropsychological function-
ing in older adults with mild cognitive impairment and insomnia ran-
domized to CBT-I or Control Group. Clin Gerontol. 2018;41(2):136-
144.
58. Cassidy-Eagle E, Unti L, Glassman J, et al. Cognitive behavioral treat-
ment for insomnia in older adults with mild cognitive impairment in
independent living facilities: a pilot study. J Sleep Disorders Med Care.
2018;1(1):1-6.
59. deOliveira AM, Radanovic M, Homem de Mello PC, et al. An inter-
vention to reduce neuropsychiatric symptoms and caregiver burden
in dementia: Preliminary results from a randomized trial of the tai-
lored activity program-outpatient version. Int. J. Geriatr. Psychiatry
2019;34(9):1301–1307. http://doi.org/10.1002/gps.4958.
60. McCurry SM, Pike KC, Vitiello MV, et al. Increasing walking and
bright light exposure to improve sleep in community-dwelling per-
sons with Alzheimer’s disease: results of a randomized, controlled
trial. J AmGeriatr Soc. 2011;59(8):1393-1402.
61. Naismith SL, Mowszowski L. Sleep disturbance in mild cognitive
impairment: a systematic review of recent findings. Curr Opin Psychi-
atry. 2018;31(2):153-159.
62. Richards KC, Lambert C, Beck CK, et al. Strength training, walk-
ing, and social activity improve sleep in nursing home and assisted
living residents: randomized controlled trial. J Am Geriatr Soc.
2011;59(2):214-223.
63. Lutz A, Dunne JD, Davidson RJ, et al. Attention regulation and moni-
toring inmeditation. Trends Cognitive Sci. 2008;12(4):163-169.
64. Lutz A, Jha AP, Dunne JD, et al. Investigating the phenomenological
matrix of mindfulness-related practices from a neurocognitive per-
spective. Am Psychol. 2015;70(7):632.
65. Malinowski P, Shalamanova L. Meditation and cognitive ageing: the
role of mindfulness meditation in building cognitive reserve. J Cogni-
tive Enhancement. 2017;1(2):96-106.
66. Luders E, Cherbuin N. Searching for the philosopher’s stone: promis-
ing links between meditation and brain preservation. Ann N Y Acad
Sci. 2016;1373(1):38-44.
67. Larouche E, Hudon C, Goulet S. Potential benefits of mindfulness-
based interventions in mild cognitive impairment and Alzheimer’s
disease: an interdisciplinary perspective. Behav Brain Res.
2015;276:199-212.
68. Klimecki O, Marchant NL, Lutz A, et al. The impact of meditation on
healthy ageing – the current state of knowledge and a roadmap to
future directions. Curr Opin Psychol. 2019;28.
69. Kurth F, Cherbuin N, Luders E. Reduced age-related degeneration of
the hippocampal subiculum in long-term meditators. Psychiatry Res:
Neuroimaging. 2015;232(3):214-218.
70. Epel E, Blackburn E, Lin J, et al. Can meditation slow rate of cellular
aging? Cognitive stress, mindfulness, and telomeres.AnnNYAcad Sci.
2009;1172:34-53.
71. Lenze EJ, Hickman S, Hershey T, et al. Mindfulness-based stress
reduction for older adults with worry symptoms and co-occurring
cognitive dysfunction. Int J Geriatr Psychiatr. 2014; 29(10):
991-1000.
72. Smart CM, Segalowitz SJ, Mulligan BP, et al. Mindfulness train-
ing for older adults with subjective cognitive decline: results from
a pilot randomized controlled trial. J Alzheimer’s Dis. 2016;52(2):
757-774.
73. Innes KE, Selfe TK, Khalsa DS, Kandati S. Effects of meditation ver-
sus music listening on perceived stress, mood, sleep, and quality
of life in adults with early memory loss: A pilot randomized con-
trolled trial. J Alzheimer’s Dis, 2016;52(4):1277–1298. http://doi.org/
10.3233/jad-151106.
74. Paller KA, Creery JD, Florczak SM, et al. Benefits of mindfulness
training for patients with progressive cognitive decline and their
caregivers. Am J Alzheimer’s. 2015;30(3):257-267.
75. WoodsB,O’Philbin L, Farrell EM, SpectorAE,OrrellM. Reminiscence
therapy for dementia. Cochrane Database Syst. Rev. 2018; http://doi.
org/10.1002/14651858.cd001120.pub3.
76. O’Philbin L, Woods B, Farrell EM, et al. Reminiscence therapy
for dementia: an abridged Cochrane systematic review of the evi-
dence from randomized controlled trials. Expert Rev Neurotherapeu-
tics. 2018;18:715-727.
77. Park K, Lee S, Yang JE, et al. A systematic review and meta-analysis
on the effect of reminiscence therapy for people with dementia. Int
Psychogeriatr. 2019;31:1581-1597.
78. Elfrink TR, Zuidema SU, Kunz M, et al. Life story books for people
with dementia: a systematic review. Int Psychogeriatr. 2018;30:1797-
1811.
79. Yen H-Y, Lin L-J. A systematic review of reminiscence therapy for
older adults in Taiwan. J Nurs Res. 2018;26:138-150.
80. Allen AP, Doyle C, Commins S, et al. Autobiographical memory, the
ageing brain and mechanisms of psychological interventions. Ageing
Res Rev. 2018;42:100-111.
81. Woods B, Bruce E, Edwards RT, et al. Reminiscence therapy for
dementia. Cochrane Database Syst Rev. 2018.
82. van der Steen JT, Smaling HJA, van der Wouden JC, et al. Music-
based therapeutic interventions for people with dementia. Cochrane
Database Syst Rev. 2018;7(7):CD003477.
83. Abraha I, Rimland JM, Trotta FM, et al. Systematic review of
systematic reviews of nonpharmacological interventions to treat
behavioural disturbances in older patientswith dementia. SENATOR-
OnTop series. BMJOpen. 2017;7(3):e012759.
84. Pedersen SKA, Andersen PN, Lugo RG, et al. Effects of music on agi-
tation in dementia: a meta-analysis. Frontiers Psychol. 2017;8(742).
85. Tsoi KK, Joyce JYC, Ng YM, et al. Receptive music therapy is more
effective than interactive music therapy to relieve behavioral and
psychological symptoms of dementia: a systematic review andmeta-
analysis. J AmMed Directors Assoc. 2018;19(7):568-576.
86. Paul DR, Yorkston KM, Klasner ER, et al. Quality of communica-
tion life scale. Manual. Rockville, MD: American Speech-Language-
Hearing Association. 2004.
16 SIKKES ET AL.
87. Behrman S, Chouliaras L, Ebmeier KP. Considering the senses in
the diagnosis andmanagement of dementia.Maturitas. 2014;77:305-
310.
88. Kovach CR. Sensoristasis and imbalance in persons with dementia. J
Nurs Scholarship. 2000;32:379-384.
89. Chung JCC, Lai CKY. Snoezelen for dementia. Cochrane Database
of Systematic Reviews, 2002. http://doi.org/10.1002/14651858.
cd003152.
90. Strøm BS, Ytrehus S, Grov EK. Sensory stimulation for persons
with dementia: a review of the literature. J Clin Nurs. 2016;25:
1805-1834.
91. Strøm BS, Engedal K, Benth JS, et al. Effect of the sonas programme
on communication in people with dementia: a randomized controlled
trial.Dement Geriatr Cognitive Disorders Extra. 2017;7:122-135.
92. Lorusso LN, Bosch SJ. Impact of multisensory environments on
behavior for people with dementia: a systematic literature review.
Gerontologist. 2018;58:e168-e179.
93. Gonzalez MT, Kirkevold M. Benefits of sensory garden and horticul-
tural activities in dementia care: a modified scoping review. J Clin
Nurs. 2014;23:2698-2715.
94. Chang Y-S, Chu H, Yang CY, et al. The efficacy of music therapy for
people with dementia: a meta-analysis of randomised controlled tri-
als. J Clinl Nurs. 2015(23-24):3425.
95. World Federation of Occupational Therapists, Statement on Occu-
pational Therapy 2012. World Federation of Occupational Ther-
apists. 2010. https://www.wfot.org/resources/statement-on-
occupational-therapy.
96. Law M, Ku Y, Zanto TP, et al. The person-environment-occupation
model: a transactive approach to occupational performance. Can J
Occup Ther. 1996;63(1):9-23.
97. Bennett S, Laver K, Radloff SV, et al. Occupational therapy for
people with dementia and their family carers provided at home:
a systematic review and meta-analysis. BMJ Open. 2019;9(11):
e026308.
98. Hsu W-Y, Ku Y, Zanto TP, et al. Effects of noninvasive brain stimula-
tion on cognitive function in healthy aging and Alzheimer’s disease: a
systematic reviewandmeta-analysis.Neurobiol Aging. 2015;36:2348-
2359.
99. Inagawa T, Narita Z, Sugawara N, et al. A meta-analysis of the
effect of multisession transcranial direct current stimulation on cog-
nition in dementia and mild cognitive impairment. Clini EEG Neurosci.
2019;50:273-282.
100. Wolinsky FD, Vander MW, Howre MB, et al. Interim analyses from
a randomised controlled trial to improve visual processing speed in
older adults: the Iowa Healthy and Active Minds Study. BMJ Open.
2011;1:e000225.
101. Lampit A, Hallock H, Valenzuela M. Computerized cognitive training
in cognitively healthy older adults: a systematic review and meta-
analysis of effect modifiers. PLoSMed. 2014;11.(11):e100175.
102. DodgeHH, Campbell I, Hayes T, et al. Use of high-frequency in-home
monitoring data may reduce sample sizes needed in clinical trials.
PLoS One. 2015;10.
103. Moher D, Altman DG, Schulz KF, et al. The CONSORT state-
ment: revised recommendations for improving the quality of
reports of parallel-group randomized trials. JAMA. 2001;285(15):
1987-1991.
104. Montgomery P, Sean G, Hopewell S, et al. Protocol for CONSORT-
SPI: an extension for social and psychological interventions. Imple-
mentation Sci. 2013;8(1):99.
105. Schulz KF, Altman DG, Moher D, CONSORT2010 statement:
updated guidelines for reporting parallel group randomised trials.
BMCMed. 2010;8(1):18.
106. Nosek BA, Alter G, Banks GC, et al. Promoting an open research cul-
ture. Science. 2015;348(6242):1422-1425.
107. Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle
intervention benefits a large elderly population at risk for cognitive
decline and dementia regardless of baseline characteristics: the FIN-
GER trial. Alzheimer’s Dement. 2018;14(3):263-270.
108. Morris MC, Tangney CC, Wang Y, et al. MIND diet associated
with reduced incidence of Alzheimer’s disease. Alzheimer’s Dement.
2015;11(9):1007-1014.
SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
How to cite this article: Sikkes SAM, Tang Y, Jutten RJ, et al.
Toward a theory-based specification of non-pharmacological
treatments in aging and dementia: Focused reviews and
methodological recommendations. Alzheimer’s Dement.
2020;1–16. https://doi.org/10.1002/alz.12188
